You are an expert biomedical scientific-writing reviewer performing a rigorous peer-review-style evaluation.

Your job: score the candidate model's generated "Methods" section against the source evidence for a methods_to_text task, using the rubric below. Be strict and specific. Punish invented numbers, invented experiments, misattributed figures, and claims that cannot be traced to the provided evidence. Reward outputs whose details are demonstrably present in the evidence.

## Rubric axes (score each 0.0 to 1.0)

- `writing_structure_compliance`
- `evidence_grounding`
- `factual_fidelity`
- `traceability`
- `hallucination_absence`

Axis definitions:

- writing_structure_compliance: Does the output open with the expected section heading and follow a plausible section structure (appropriate level of detail, logical flow, typical subsections for the task family)?
- evidence_grounding: Is every non-trivial claim traceable to specific content in the source evidence? Penalize free-floating claims.
- factual_fidelity: Do quantitative values, qualifiers ("significantly", "modestly"), organisms, time points, sample sizes, and cited figures/tables exactly match the source? Any mismatch is a serious deduction.
- traceability: Are evidence identifiers, section pointers (e.g. "methods_section", "abstract_section"), figure/table references, or accessions cited where useful? 0.0 if there are zero references; 1.0 if they are pervasive and correct.
- hallucination_absence: Is the output free of fabricated content (made-up citations, phantom experiments, invented numerical values)? 1.0 = no hallucinations found; 0.0 = at least one clear fabrication.

## Pass threshold

An axis is considered passing at >= 0.6. overall_pass is true if and only if every axis is at or above that threshold.

## Source evidence

## Abstract
Previously no mouse gastric cancer cell lines have been available for transplantation into C57BL/6 mice. However, a gastric cancer model in immunocompetent mice would be useful for analyzing putative therapies. N-Methyl-N-nitrosourea (MNU) was given in drinking water to C57BL/6 mice and p53 heterozygous knockout mice. Only 1 tumor from a p53 knockout mouse could be cultured and the cells s.c. transplanted into a C57BL/6 mouse. We cultured this s.c. tumor, and subcloned it. mRNA expression in the most aggressive YTN16 subline was compared to the less aggressive YTN2 subline by microarray analysis, and fibroblast growth factor receptor 4 (FGFR4) in YTN16 cells was knocked out with a CRISPR/Cas9 system and inhibited by an FGFR4 selective inhibitor, BLU9931. These transplanted cell lines formed s.c. tumors in C57BL/6 mice. Four cell lines (YTN2, YTN3, YTN5, YTN16) were subcloned and established. Their in vitro growth rates were similar. However, s.c. tumor establishment rates, metastatic rates, and peritoneal dissemination rates of YTN2 and YTN3 were lower than for YTN5 and YTN16. YTN16 established 8/8 s.c. tumors, 7/8 with lung metastases, 3/8 with lymph node metastases and 5/5 with peritoneal dissemination. FGFR4 expression by YTN16 was 121-fold higher than YTN2. FGFR4-deleted YTN16 cells failed to form s.c. tumors and showed lower rates of peritoneal dissemination. BLU9931 significantly inhibited the growth of peritoneal dissemination of YTN16. These studies present the first transplantable mouse gastric cancer lines. Our results further indicate that FGFR4 is an important growth signal receptor in gastric cancer cells with high FGFR4 expression.

## Results
3 RESULTS Five gastric cancers were established in 5 C57BL/6 mice and 7 gastric cancers were established in 4 p53 heterozygous knockout mice. We prepared primary cultures from all 12 of the gastric cancers; however, only 1 gastric cancer from a male heterozygous p53 knockout mouse could be cultured long term. Histological analysis of the original tumor from which the cell lines were derived is shown in Figure 2 . The primary tumor arose at the fundic‐antral border of the glandular stomach and was a well‐differentiated adenocarcinoma containing class III mucin, and immunohistochemically negative for pepsinogen 1. From these findings, the primary tumor was classified as an antral phenotype, which possibly arose from either TFF2 (spasmolytic polypeptide) expressing metaplasia (SPEM) or from pyloric glands, not from fundic glands without metaplastic change, and showing behavior more aggressive than fundic gland‐type gastric cancer. Figure 2 Primary tumor from which cell lines were established. (A) Hematoxylin and eosin staining (10×). (B) Higher magnification (40×). Tumor shows a well‐differentiated phenotype. (C) Pepsinogen 1 was negative in the tumor. (D) Class III mucin was positive in the tumor and thus the tumor was classified as a pyloric phenotype Microscopic features of YTN2, YTN3, YTN5, and YTN16 are shown in Figure 3 A‐D. YTN2 and YTN3 tended to have giant cells, but there were no remarkable differences among the cell lines. Growth curves of the cell lines are shown in Figure 3 E. There were no differences in the growth rates among the cell lines. Figure 3 Microscopic features of growing cell lines in vitro. (A) YTN 2, (B) YTN 3, (C) YTN 5, (D) YTN 16. (E) Growth curves of the cell lines. Growth rates were not different among the cell lines. (F) PCR for WT p53 and mutant allele of p53. The subcloned cell lines were lacking in WT p53, suggesting LOH Results of P53 PCR are shown in Figure 3 F. The original tumor (466T2) arose in a p53 heterozygous knockout mouse and showed a WT p53 band and a knockout band, consistent with a WT p53 and a knockout allele of p53. However, DNA was extracted from the whole tissue of the cancer, not microdissected, and thus there was a possibility of contaminating interstitial tissue. The WT p53 band in the primary cultured cells was much weaker than in the original cancer, still suggesting a possibility of fibroblast contamination. The cloned cell lines, YTN2, YTN3, YTN5, and YTN16 had only a mutant p53 band, suggesting LOH. We implanted 5 × 10 6 cells of YTN2, YTN3, YTN5, and YTN16 lines s.c. into C57BL/6 mice. Tumorigenicity rates for YTN2, YTN5, and YTN16 were 100%, but were only 37.5% for YTN3. These tumorigenicity rates are described in Table 1 , and the growth curves for s.c. tumor with representative macroscopic mouse s.c. tumors are shown in Figure 4 . The growth rates of s.c. implanted YTN2 and YTN3, which formed tumors, were similar. YTN5 and YTN16 showed an accelerated growth rate. Metastatic rates of s.c. tumor, 12 weeks after implantation, are also shown in Table 1 . The metastatic rates for lung and lymph nodes were the lowest for YTN3. Peritoneal dissemination rates of YTN2 (40%) and YTN3 (20%) were much lower than for YTN5 (100%) and YTN16 (100%) (Table 1 ). Table 1 Tumorigenicity and metastasis rates for cell lines in the present study Metastasis a Cell line Tumorigenicity in mouse (%) Lung Lymph node Peritoneum YTN 2 7/7 (100) 5/7 2/7 2/5 YTN 3 3/8 (37.5) 2/3 0/3 1/5 YTN 5 11/11 (100) 9/11 3/11 5/5 YTN 16 8/8 (100) 7/8 3/8 5/5 a Tumorigenicity and spontaneous metastasis of the s.c. injection of 5 × 10 6 cells. John Wiley & Sons, Ltd Figure 4 Growth curves of s.c. tumor with representative macroscopic mouse s.c. tumors. Growth curves of (A) YTN 2, (B) YTN 3, (C) YTN 5, (D) YTN 16. Macroscopic mouse cutaneous tumors of (E) YTN 3, (F) YTN 16 Microscopic appearance of s.c. tumor, lung metastasis, lymph node metastasis, and peritoneal dissemination is shown in Figure 5 . The tumors were histologically similar among YTN, even with the size difference and different metastatic rates of the tumor. There was no lymph node metastasis for YTN3. Macroscopically, there was 1 peritoneal metastasis of YTN3; however, the nodule was so small that we could not find it microscopically after tissue processing. Figure 5 Microscopic appearance of s.c. tumor, lung metastasis, lymph node metastasis, and peritoneal dissemination of YTN 2, YTN 3, YTN 5, and YTN 16. (A‐D) S.c. tumor of YTN ...

## Figure captions
1. Figure 1. Establishment of mouse gastric cancer cell lines. Mice were given drinking water ad libitum containing 30 ppm N ‐methyl‐ N ‐nitrosourea ( MNU ) on alternate weeks for a total exposure of 5 weeks and killed at 40 weeks. Fresh gastric tumor tissues were washed and primary cultured, removing fibroblasts. Cells were injected into C57 BL /6 mouse s.c. The established tumor was excised and cultured. From the 2 dishes, 2 single cell cloned cell lines each were established. The 2 cell lines from 1 dish were named YTN 2 and YTN 3. The other 2 cell lines from the other dish were named YTN 5...
2. Figure 2. Primary tumor from which cell lines were established. (A) Hematoxylin and eosin staining (10×). (B) Higher magnification (40×). Tumor shows a well‐differentiated phenotype. (C) Pepsinogen 1 was negative in the tumor. (D) Class III mucin was positive in the tumor and thus the tumor was classified as a pyloric phenotype
3. Figure 3. Microscopic features of growing cell lines in vitro. (A) YTN 2, (B) YTN 3, (C) YTN 5, (D) YTN 16. (E) Growth curves of the cell lines. Growth rates were not different among the cell lines. (F) PCR for WT p53 and mutant allele of p53. The subcloned cell lines were lacking in WT p53, suggesting LOH
4. Figure 4. Growth curves of s.c. tumor with representative macroscopic mouse s.c. tumors. Growth curves of (A) YTN 2, (B) YTN 3, (C) YTN 5, (D) YTN 16. Macroscopic mouse cutaneous tumors of (E) YTN 3, (F) YTN 16
5. Figure 5. Microscopic appearance of s.c. tumor, lung metastasis, lymph node metastasis, and peritoneal dissemination of YTN 2, YTN 3, YTN 5, and YTN 16. (A‐D) S.c. tumor of YTN 2‐16. (E‐H) Lung metastasis of YTN 2‐16. (I‐K) Lymph node metastasis of YTN 2, YTN 5, YTN 16. (L‐N) Peritoneal dissemination of YTN 2, YTN 5, YTN 16. Lymph node metastasis was not detected in YTN 3. Small peritoneal dissemination was macroscopically detected for YTN 3, without confirmation microscopically. Microscopic morphology was not remarkably different among the cell lines
6. Figure 6. Fgfr4 disrupted YTN 16. (A) F7 has an insertion of adenine in exon 3 of Fgfr4, and Fgfr4 is disrupted by a frameshift termination. (B) F87 has a deletion of adenine in exon 3 of Fgfr4, and Fgfr4 is disrupted by a frameshift termination. (C) Growth rates of YTN 16, F7 and F87 were not different in vitro. (D‐F) Microscopic morphology of YTN 16, F7, and F87 showed no difference in vitro. (G‐I) F7 and F87 do not form s.c. tumors. (J‐L) F7 and F87 formed very small foci of peritoneal dissemination in 2 out of 5 mice. YTN 16 formed large nodules in 5 out of 5 mice in the same period. (M...
7. Figure 7. BLU 9931 treated YTN 16. (A,B) Growth of s.c. transplanted YTN 16 was blunted with BLU 9931 30 mg/kg b.i.d. treatment. (C,D) Growth of peritoneal dissemination of YTN 16 is remarkably inhibited with BLU 9931. (E,G) Microscopic appearance of peritoneal dissemination of YTN 16 (E) without BLU 9931 and (G) with BLU 9931 treatment for 3 weeks. (F,H) Microscopic features of s.c. tumor of YTN 16 (F) without BLU 9931 and (H) with BLU 9931 treatment for 3 weeks. YTN 16 tumor under treatment with BLU 9931 does not form glandular structures. (I,K) pSTAT 3, (J,L) pERK , (M,N) pAKT expression...

## Table snippets
1. Table 1. Tumorigenicity and metastasis rates for cell lines in the present study | Metastasis a; Cell line; Tumorigenicity in mouse (%); Lung; Lymph node; Peritoneum
2. Table 2. Top 50 genes expressed in YTN5 and YTN16 higher than in YTN2 and YTN3 | Gene symbol; N16/N2; N5/N2; N16/N3; N5/N3; Klhl13

## Candidate output (to be judged)

Methods

The methods for establishing and characterizing novel transplantable mouse gastric cancer cell lines, and for investigating the functional role of fibroblast growth factor receptor 4 (FGFR4), are described herein. A full account of the experimental procedures is provided in the **methods_section** of the source paper. In brief, gastric tumors were induced in C57BL/6 and p53 heterozygous knockout mice by administering N-Methyl-N-nitrosourea (MNU) at 30 ppm in drinking water on alternate weeks for a total of five weeks, with mice euthanized at 40 weeks. Primary cultures were attempted from all tumors, but only one tumor from a male p53 heterozygous knockout mouse could be propagated long-term. Cells from this culture were subcutaneously transplanted into a C57BL/6 mouse, and the resulting tumor was re-cultured and subcloned to establish four distinct cell lines (YTN2, YTN3, YTN5, YTN16). The **results_section** details the subsequent *in vitro* and *in vivo* characterizations. For *in vivo* analysis, 5 x 10^6 cells were implanted subcutaneously into syngeneic C57BL/6 mice to assess tumorigenicity, growth, and spontaneous metastasis. Histological and immunohistochemical analyses of the original primary tumor and subsequent transplants were performed, as depicted in the **section_text** of Figure 2. *In vitro* growth rates were compared, and p53 status was assessed by PCR. Microarray analysis was conducted to compare mRNA expression between the more aggressive YTN16 subline and the less aggressive YTN2 subline. Based on this **evidence**, FGFR4 was selected for functional study. FGFR4 was knocked out in YTN16 cells using a CRISPR/Cas9 system, and its activity was pharmacologically inhibited using the selective inhibitor BLU9931 *in vivo*. The outcomes of these interventions on tumor growth and dissemination are summarized in the **abstract_section**. Specific details regarding mouse numbers per group, exact dosing schedules for BLU9931, and the complete microarray methodology are not provided in the available evidence.

## Output format

Respond with ONLY a single JSON object. No prose before or after. No markdown code fences. The JSON must match this schema exactly:

{
  "axis_scores": {
    "writing_structure_compliance": <float 0.0-1.0>,
    "evidence_grounding": <float 0.0-1.0>,
    "factual_fidelity": <float 0.0-1.0>,
    "traceability": <float 0.0-1.0>,
    "hallucination_absence": <float 0.0-1.0>
  },
  "axis_rationales": {
    "writing_structure_compliance": "<1-3 sentences>",
    "evidence_grounding": "<1-3 sentences>",
    "factual_fidelity": "<1-3 sentences>",
    "traceability": "<1-3 sentences>",
    "hallucination_absence": "<1-3 sentences>"
  },
  "grounding_issues": [
    "<specific concern citing the exact claim and why it is unsupported or inconsistent with the evidence>"
  ],
  "overall_pass": <true or false>
}